An FMD improved the clinicalresponse to neoadjuvant chemotherapy as compared to a regular diet in HER2-negativeearly breast cancer patients receiving chemotherapy.12 Radiologically complete orpartial response occurs more often in patients using the FMD [odds ratio (OR):3.168, p = 0.039] and a pathological response was more likely tooccur in patients using the FMD (OR: 4.109, p = 0.016). The gene discussed is ERBB2; the disease is breast cancer.